Royalty Pharma plc (RPRX) company profile
Close on Nov 17, 2026Market cap $39.49BP/E 39.0Yield –
About Royalty Pharma
Pharmaceutical Preparations, SIC 2834
Royalty Pharma acquires biopharmaceutical royalties and finances life sciences innovation. The company collaborates with academic institutions, non-profit organizations, biotechnology firms, and global pharmaceutical corporations across the biopharmaceutical development spectrum. Its primary offerings comprise third-party royalties on approved medicines, synthetic royalties created on late-stage candidates, and complementary capital arrangements including unsecured debt, equity investments, and launch funding. The company generates receipts from rights tied directly to end-market sales of commercial treatments across diverse therapeutic fields such as rare diseases, oncology, immunology, neuroscience, and respiratory care.
The business manages a portfolio encompassing more than 35 commercial therapies and 20 development-stage candidates. Its underlying royalty agreements grant exposure to global pharmaceutical sales across international territories, including the United States, non-U.S. markets, and early-stage licensing opportunities in China, though certain specific interests exclude territories such as China. The provided text does not identify the location of the company's corporate headquarters.
Summary of the business section of Royalty Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Royalty Pharma plc
- Founded
- 1996
- Headquarters
- New York, NY
- Address
- 110 East 59th Street 10022
- Phone
- (212) 883-0200
- Website
- royaltypharma.com
- Employees
- 100, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- X0
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- RPRX
- Exchange
- Nasdaq
- IPO date
- Jun 17, 2020
- Shares outstanding
- 575M, Jul 31, 2026
- Public float
- $16.70B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1802768
- CUSIP
- G7709Q104
- FIGI
- BBG00V1L5YZ5
- Share class FIGI
- BBG00V1L5ZR1
- LEI
- 549300FGFN7VOK8BZR03
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Pablo G. Legorreta | CEO, Chairman of the Board, Director | 28,011,146 |
| Marshall Urist | EVP, Research & Investments | 1,530,889 |
| Christopher Hite | EVP & Chairman, Partnering | 1,539,512 |
| Terrance P. Coyne | EVP & CFO | 2,096,289 |
| Arthur Richard McGivern | EVP, Investments & GC | – |
| George W. Lloyd | EVP, Investments & CLO | 2,724,616 |
| Bonnie L. Bassler | Director | 79,823 |
| David C. Hodgson | Director | 37,873 |
| Elizabeth H. Weatherman | Director | 13,103 |
| Vlad Coric | Director | 15,343 |
| Ted W. Love | Director | 58,393 |
| Gregory Norden | Director | 196,348 |
| Carole Ho | Director | 13,103 |
| Catherine M. Engelbert | Director | 55,673 |
| Henry A. Fernandez | Director | 123,524 |
| Errol B. Desouza | Director | 81,352 |
| Pharma plc Royalty | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $937.50K | $82.51M | $1.32M | $85 | $206 |
| FY2024 | – | $191.32M | $1.26M | $57 | $170 |
| FY2023 | – | $26.79M | $4.56M | $61 | $152 |
| FY2022 | – | $45.76M | $4.35M | $82 | $141 |
| FY2021 | – | $57.04M | $3.84M | $81 | $128 |
| FY2020 | – | $51.53M | $3.46M | $113 | $106 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Total | vs. prior year |
|---|---|---|---|
| Pablo Legorreta Chief Executive Officer | $937.50K | $937.50K | – |
| Terrance Coyne Executive Vice President & Chief Financial Officer | $1.32M | $1.32M | +5% |
| Christopher Hite Executive Vice President & Vice Chairman | $1.32M | $1.32M | +5% |
| George Lloyd Senior Advisor; former Executive Vice President, Chief Legal Officer & Investments | $1.32M | $1.32M | +5% |
| Marshall Urist, M.D., Ph.D. Executive Vice President, Research & Investments | $1.32M | $1.32M | +5% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 17, 2020
- Offer price
- $28.00
- Securities offered
- 77,681,670
- Gross proceeds
- $2.18B
- Exchange
- Nasdaq
- First trading day
- Jun 16, 2020
- First-day close
- $44.50+58.9%
- Lock-up ends (est.)
- Dec 13, 2020
“The initial public offering price is $28.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 100 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 19, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 11, 2025 | Merger vote | Definitive merger proxy statement |
| Apr 4, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 21, 2021 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jun 17, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 15, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?